FDA Clears First-of-Its-Kind Cell Therapy to Spare Transplant Patients From Chronic GVHD

What This Article Covers

On June 30, 2026, the FDA approved Tregzi (Orca-T), a donor-derived cell therapy from Orca Bio that is designed to protect patients from one of the most feared long-term complications of a stem cell transplant: chronic graft-versus-host disease (GVHD). It is the first regulatory T-cell (Treg) therapy of its kind to reach approval, and the pivotal trial behind it reported a striking improvement in one-year survival free of chronic GVHD compared with a standard transplant. This article walks through what was approved, what the trial actually showed, who it's for, and the real limitations patients and clinicians should keep in mind.

What Happened

For decades, an allogeneic hematopoietic stem cell transplant (allo-HSCT) — using a matched donor's stem cells to treat high-risk leukemias and related blood cancers — has come with a brutal trade-off. The transplant can cure the cancer, but the donor's immune cells, transplanted along with the stem cells, can turn on the patient's own body. That's graft-versus-host disease, and in its chronic form it can mean years of skin, gut, liver, lung, or eye damage, lifelong immunosuppressive drugs, and a meaningfully worse quality of life for survivors.

Tregzi takes direct aim at that trade-off. Rather than transplanting an unmanipulated donor graft, Orca Bio's manufacturing process reformulates the donor material into three purified components — hematopoietic stem and progenitor cells, regulatory T cells (the subset of immune cells whose job is to dampen immune attacks), and a controlled dose of conventional T cells. The regulatory T cells are infused first, ahead of the stem cells, to help establish immune tolerance before the rest of the graft arrives.

What the Phase 3 Trial Actually Showed

The approval rests on the randomized PRECISION-T trial, which enrolled 187 adults with high-risk blood cancers — acute myeloid leukemia, acute lymphoblastic leukemia, high-risk myelodysplastic syndrome, and mixed-phenotype acute leukemia — who had an 8/8 HLA-matched donor available. Patients were randomized to receive either Tregzi plus a single immunosuppressant (tacrolimus) or a conventional unmanipulated transplant plus the standard two-drug regimen (tacrolimus and methotrexate).

The primary endpoint — survival free of chronic GVHD at one year — favored Tregzi decisively:

• Chronic GVHD-free survival at 12 months: 78% with Tregzi versus 38.4% with conventional transplant (hazard ratio 0.26)
• Moderate-to-severe chronic GVHD at 12 months: approximately 12.6% with Tregzi versus 44.0% with conventional transplant
• Neutrophil recovery: all Tregzi-treated patients in the trial achieved neutrophil recovery (a key marker of the transplant engrafting successfully) within 28 days

The therapy also carried Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA, reflecting both the seriousness of the disease and the strength of the early data that supported its path through review.

Why This Matters for Patients

Chronic GVHD isn't a footnote — it's one of the main reasons allo-HSCT, despite being curative for many blood cancers, remains such a hard treatment to recommend and endure. Patients who survive the transplant itself can spend years managing a disease their own treatment caused. A therapy that cuts serious chronic GVHD from roughly 44% down to about 13%, in a randomized trial rather than a small single-arm study, is the kind of result transplant physicians have been chasing for a long time. This was tested head-to-head against a real, currently used standard of care, in a trial large and rigorous enough to support full FDA approval rather than just an early-phase signal.

What Comes Next, and the Caveats That Matter

Positive as this is, several limits are built directly into the approval and should not be glossed over:

• Narrow eligibility: Tregzi is approved specifically for adults with an 8/8 HLA-matched donor. Patients without a fully matched donor are not covered by this approval and are not represented in the PRECISION-T data.
• An open comparison the trial didn't settle: it remains unclear how Tregzi compares with another widely used GVHD-prevention strategy, post-transplant cyclophosphamide, since the trial compared Tregzi to a different conventional regimen, not to that specific alternative.
• Durability beyond one year is still being tracked. The headline results are at 12 months; longer-term outcomes, including relapse risk and whether the GVHD benefit holds up over years, will take more follow-up data to establish.
• Manufacturing is demanding and time-sensitive, which could affect how widely and reliably the therapy can be delivered outside major transplant centers.
• Cost is substantial, raising real questions about access and insurance coverage as uptake begins.

None of this undercuts what the trial demonstrated. It does mean Tregzi is, for now, an option for a specific, well-defined group of transplant-eligible patients — not a universal replacement for existing GVHD-prevention strategies.

Bottom Line

The FDA's approval of Tregzi marks the first time a regulatory T-cell therapy has reached the market specifically to prevent chronic graft-versus-host disease, and the randomized trial behind it showed a genuinely large improvement — chronic GVHD-free survival roughly doubling, from about 38% to 78%, versus a real standard-of-care comparator. For patients facing a matched-donor transplant for high-risk leukemia or related blood cancers, that is meaningful, well-documented progress on one of transplantation's oldest and most damaging complications. At the same time, the approval applies only to HLA-matched donor settings, leaves open how Tregzi stacks up against other modern GVHD-prevention regimens, and comes with a demanding manufacturing timeline and a substantial price tag — all factors that will shape how quickly, and for whom, this approach becomes part of routine transplant care.